Current trends and advancements in utilizing endoscopic cyclophotocoagulation for the Treatment of Glaucoma

Glaucoma ranks as the second most prevalent cause of global blindness. Presently, the reduction of intraocular pressure (IOP) stands as the sole efficacious method for addressing this condition. Endoscopic cyclophotocoagulation (ECP) is designed to mitigate aqueous humor production by inducing coagulation or closure of the ciliary body. Since its inception in 1990s, ECP has emerged as a pivotal modality in the therapeutic armamentarium for glaucoma. This review primarily elucidates the instrumentation employed in ECP for the treatment of glaucoma, the mechanisms underlying its efficacy in glaucoma management, and a comparative analysis of ECP in relation to other modalities for anti-glaucoma treatment. Furthermore, it examines the contemporary clinical utilization of ECP in glaucoma therapy, as well as the prevalent postoperative complications and their preventive measures. We anticipate that the role of ECP in the treatment of glaucoma will persistently evolve alongside advancements in the field. Particularly noteworthy is its expanding applicability in glaucoma therapy and its increasingly vital role in personalized comprehensive treatment approaches.